Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
Clinical trial NCT05275205 · COMPLETED
Trial details
- NCT number
- NCT05275205
- Sponsor
- Unity Biotechnology, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-02
- Primary completion
- 2023-02-15
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.